Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Pfizer Completes Acquisition of Global Blood Therapeutics

October 05, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

October 04, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

October 03, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

September 26, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Declares Fourth-Quarter 2022 Dividend

September 22, 2022

From Pfizer Inc.

Via Business Wire

Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries

September 22, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts

September 20, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

September 19, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents

September 15, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022

September 14, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

September 14, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union

September 12, 2022

From Pfizer Inc.

Via Business Wire

FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata

September 09, 2022

From Pfizer Inc.

Via Business Wire

FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women

September 07, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

September 06, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action

September 06, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences

September 01, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

September 01, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

August 31, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

August 26, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate

August 25, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

August 22, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age

August 23, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

August 19, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants

August 12, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

August 08, 2022

From Pfizer Inc.

Via Business Wire

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

August 08, 2022

From Pfizer Inc.

Via Business Wire

PFIZER REPORTS SECOND-QUARTER 2022 RESULTS

July 28, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™

June 30, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

June 29, 2022

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.